HER2-Positive Bladder Cancer: New Drug vs Standard Chemotherapy
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug (disitamab vedotin) combined with immunotherapy against the standard chemotherapy-immunotherapy combination for muscle-invasive bladder cancer that expresses HER2 protein. The goal is to see if the new approach works better and is safer for patients before bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with muscle-invasive bladder cancer (cancer has grown into the muscle layer of the bladder) at stage cT2-T4aN0/1M0, with leftover cancer after initial TURBT procedure
- Your cancer cells must show HER2 protein (tested by immunohistochemistry) at level 1+ or higher
- No prior chemotherapy or immunotherapy treatments for this bladder cancer
- Blood work shows adequate kidney, liver, and heart function, with kidney function clearance >40 mL/min
- Good overall health status (ECOG 0-1: able to do normal activities or mildly limited)
- Willing to use effective birth control for 6 months after treatment (applies to men and women of childbearing age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—an antibody-drug conjugate (Disitamab Vedotin) and an immunotherapy (Toripalimab)—given for different lengths of time to treat muscle-invasive bladder cancer. The goal is to preserve the bladder while controlling the cancer.
This study tests a combination of two drugs given directly into the bladder for a type of early-stage bladder cancer that has a specific protein marker called HER2. The goal is to see if the combination helps prevent the cancer from coming back.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of targeted therapy (Disitamab Vedotin), immunotherapy (PD-1 inhibitor), and radiation to help avoid bladder removal. It is for people with HER2-high muscle-invasive bladder cancer who have had a maximal transurethral resection (TURBT).
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This trial studies a combination of two drugs for bladder cancer that has not spread beyond the bladder. It aims to help patients who want to avoid bladder removal surgery, potentially preserving their bladder.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.